Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications

ConclusionsPatients treated with siponimod showed a T and B lymphocyte reduction, especially CD4+, CD3+CD20+ and na ïve regulatory T cells and memory regulatory B cells. Disability progression while on siponimod treatment was associated with a less pronounced effect on B and CD3+CD20+ lymphocytes.
Source: Journal of Neurology - Category: Neurology Source Type: research